Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.

Breast Cancer Res · 2011 · PMC3326564 · PMID 22126395

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the adjuvant therapy group, both univariate and multivariate analysis showed no significant difference in prognosis between the anthracyclin-based regimen and 5FU-based regimen, although patients with the former regimen showed a trend-level improvement in prognosis over those with the latter.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.